These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 19609237)

  • 1. Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release.
    Amann M; D'Argouges S; Lorenczewski G; Brischwein K; Kischel R; Lutterbuese R; Mangold S; Rau D; Volkland J; Pflanz S; Raum T; Münz M; Kufer P; Schlereth B; Baeuerle PA; Friedrich M
    J Immunother; 2009 Jun; 32(5):452-64. PubMed ID: 19609237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3.
    Amann M; Brischwein K; Lutterbuese P; Parr L; Petersen L; Lorenczewski G; Krinner E; Bruckmeier S; Lippold S; Kischel R; Lutterbuese R; Kufer P; Baeuerle PA; Schlereth B
    Cancer Res; 2008 Jan; 68(1):143-51. PubMed ID: 18172306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective inhibition of IDO1, D-1-methyl-tryptophan (D-1MT), effectively increased EpCAM/CD3-bispecific BiTE antibody MT110 efficacy against IDO1
    Hong R; Zhou Y; Tian X; Wang L; Wu X
    Int Immunopharmacol; 2018 Jan; 54():118-124. PubMed ID: 29128855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class.
    Brischwein K; Parr L; Pflanz S; Volkland J; Lumsden J; Klinger M; Locher M; Hammond SA; Kiener P; Kufer P; Schlereth B; Baeuerle PA
    J Immunother; 2007; 30(8):798-807. PubMed ID: 18049331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans.
    Amann M; Friedrich M; Lutterbuese P; Vieser E; Lorenczewski G; Petersen L; Brischwein K; Kufer P; Kischel R; Baeuerle PA; Schlereth B
    Cancer Immunol Immunother; 2009 Jan; 58(1):95-109. PubMed ID: 18594818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lysis of cancer cells by autologous T cells in breast cancer pleural effusates treated with anti-EpCAM BiTE antibody MT110.
    Witthauer J; Schlereth B; Brischwein K; Winter H; Funke I; Jauch KW; Baeuerle P; Mayer B
    Breast Cancer Res Treat; 2009 Oct; 117(3):471-81. PubMed ID: 18819003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mode of cytotoxic action of T cell-engaging BiTE antibody MT110.
    Haas C; Krinner E; Brischwein K; Hoffmann P; Lutterbüse R; Schlereth B; Kufer P; Baeuerle PA
    Immunobiology; 2009; 214(6):441-53. PubMed ID: 19157637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Biodistribution of a CD3 and EpCAM Bispecific T-Cell Engager Is Driven by the CD3 Arm.
    Suurs FV; Lorenczewski G; Stienen S; Friedrich M; de Vries EGE; de Groot DJA; Lub-de Hooge MN
    J Nucl Med; 2020 Nov; 61(11):1594-1601. PubMed ID: 32284393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110.
    Deisting W; Raum T; Kufer P; Baeuerle PA; Münz M
    PLoS One; 2015; 10(10):e0141669. PubMed ID: 26510188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.
    Bellone S; Black J; English DP; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Ferrari F; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
    Am J Obstet Gynecol; 2016 Jan; 214(1):99.e1-8. PubMed ID: 26272866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concentrations of EpCAM ectodomain as found in sera of cancer patients do not significantly impact redirected lysis and T-cell activation by EpCAM/CD3-bispecific BiTE antibody MT110.
    Petsch S; Gires O; Rüttinger D; Denzel S; Lippold S; Baeuerle PA; Wolf A
    MAbs; 2011; 3(1):31-7. PubMed ID: 21107020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of long-lasting antitumor immunity by concomitant cell therapy with allogeneic lymphocytes and trifunctional bispecific antibody.
    Morecki S; Lindhofer H; Yacovlev E; Gelfand Y; Ruf P; Slavin S
    Exp Hematol; 2008 Aug; 36(8):997-1003. PubMed ID: 18495330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient tumor cell lysis by autologous, tumor-resident T lymphocytes in primary ovarian cancer samples by an EP-CAM-/CD3-bispecific antibody.
    Wimberger P; Xiang W; Mayr D; Diebold J; Dreier T; Baeuerle PA; Kimmig R
    Int J Cancer; 2003 Jun; 105(2):241-8. PubMed ID: 12673686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3.
    Mau-Sørensen M; Dittrich C; Dienstmann R; Lassen U; Büchler W; Martinius H; Tabernero J
    Cancer Chemother Pharmacol; 2015 May; 75(5):1065-73. PubMed ID: 25814216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [T-cells activated with a trifunctional bi-specific antibody in head and neck cancer].
    Gronau S; Schmitt M; Reinhardt P; Wiesneth M; Riechelmann H
    Laryngorhinootologie; 2005 Nov; 84(11):822-8. PubMed ID: 16358189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells.
    Cioffi M; Dorado J; Baeuerle PA; Heeschen C
    Clin Cancer Res; 2012 Jan; 18(2):465-74. PubMed ID: 22096026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An epithelial cell adhesion molecule- and CD3-bispecific antibody plus activated T-cells can eradicate chemoresistant cancer stem-like pancreatic carcinoma cells in vitro.
    Umebayashi M; Kiyota A; Koya N; Tanaka H; Onishi H; Katano M; Morisaki T
    Anticancer Res; 2014 Aug; 34(8):4509-19. PubMed ID: 25075094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct.
    Schlereth B; Fichtner I; Lorenczewski G; Kleindienst P; Brischwein K; da Silva A; Kufer P; Lutterbuese R; Junghahn I; Kasimir-Bauer S; Wimberger P; Kimmig R; Baeuerle PA
    Cancer Res; 2005 Apr; 65(7):2882-9. PubMed ID: 15805290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New gene-immunotherapy combining TRAIL-lymphocytes and EpCAMxCD3 Bispecific antibody for tumor targeting.
    Groth A; Salnikov AV; Ottinger S; Gladkich J; Liu L; Kallifatidis G; Salnikova O; Ryschich E; Giese N; Giese T; Momburg F; Büchler MW; Moldenhauer G; Herr I
    Clin Cancer Res; 2012 Feb; 18(4):1028-38. PubMed ID: 22228630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro.
    Ferrari F; Bellone S; Black J; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Menderes G; Litkouhi B; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
    J Exp Clin Cancer Res; 2015 Oct; 34():123. PubMed ID: 26474755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.